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Background: right ventricular dysfunction can occur as a consequence of mitral valve disease and seems to be a prognostic marker in patients 
undergoing surgery. The only parameter related to right ventricular function (RVF) included in cardiac surgical risk scores is pulmonary hypertension. 
Our aims were to analyze RVF parameters in patients undergoing mitral surgery and their relationship with post surgery outcomes.
Methods: 109 consecutive patients underwent mitral valve surgery during 2009-2010. RVF evaluation was performed by invasive hemodynamic 
pressure study and echocardiography. Outcomes: heart failure (HF), death and the combined event (CE) of HF, death and NYHA functional class >2.
Results: mean age was 69±9,6 years; 54% women. Indication for surgery was mitral regurgitation in 86%. Mitral valve replacement was performed 
in 71%, tricuspid annuloplasty in 49% and coronary surgery in 20%. Mean follow up was 783±377 days. The relationships between right ventricular 
dysfunction and outcomes are shown in the table. Multivariate analysis (COX regression) included EUROSCORE>10%, SFRV (shortening fraction 
of the right ventricle) 18 cm2 and tricuspid annuloplasty. EUROSCORE >10% (HR= 3,33; p=0,00) and TAPSE ≤16mm (HR= 2,19; p=0,03) were 
independent predictors of CE.
Conclusions: right ventricular dysfunction (especially TAPSE≤16mm ) is associated with a poor prognosis in patients undergoing mitral valve 
surgery. RVF should be considered before surgery.
Incidence Free Event Survival p value (Log Rank Test)
TAPSE≤16 mm
HF 39% vs 24% 400 vs 595 days 0,042
Death 39% vs 10% 453 vs 705 days 0,001
CE 54% vs 35% 324 vs 529 days 0,021
SFRV <32%
Death 38% vs 13% 512 vs 684 days 0,019
Severe pulmonary hypertension
HF 58% vs 21% 300 vs 617 days 0,000
CE 63% vs 34% 284 vs 530 days 0,007
